ie Adequan Alenza and Tramadol are not appropriate for Renal dogs.

This study has some limitations most important of which is the low number of dogs evaluated. The low prevalence of ADH and the fact that many dogs are treated surgically made it difficult to conduct a prospective study. This limitation led to the necessity of including dogs diagnosed over a large period of time to collect enough dogs for statistical analysis. The use of trilostane to control hypercortisolism in dogs began in the last decade and therefore dogs included in this group are more recent cases. Despite all of these factors, there were no significant differences regarding population attributes of dogs in both groups (trilostane and mitotane). Another limitation of this study is the lack of histologic data in most cases because differentiating adrenocortical adenoma from carcinoma may affect survival times in these dogs. Despite these limitations, the clinical data obtained in this study may help when choosing a medical treatment for dogs with ADH.

Alenza Chewable Tablets are a multi-system nutritional supplement for dogs

Alenza products provide multi-system support for whole body comfort in aging and active dogs. They help neutralize free radicals, including those that have the potential to cause damage in the joints and skin, for a balanced approach to supporting your pet’s ongoing health.

Alenza for Dogs Multi-System Support · Alenza

Purchase Alenza chewable tablets for large, medium, small dogs - Allivet When censoring the 2 dogs in the trilostane group that underwent adrenalectomy, the differences in the survival time of dogs treated with mitotane compared with those treated with trilostane were not statistically significant (15.42 ± 3.2 months for mitotane group and 20.10 ± 5.3 months for trilostane group; Fig ).

Alenza for Dogs Multi-System Support

When censoring the 2 dogs in the trilostane group that underwent adrenalectomy, the differences in the survival time of dogs treated with mitotane compared with those treated with trilostane were not statistically significant (15.42 ± 3.2 months for mitotane group and 20.10 ± 5.3 months for trilostane group; Fig ).

FREE shipping and the BEST customer service!


As with all non-prescription products, you should consult your dog's veterinarian before giving your dog Alenza. They can decide what dose is specifically best for your pet and if your pet is a good candidate for Alenza supplementation. The manufacturer recommends for dogs 25 lbs and under to use the small dog formulation and give 1 tablet per day for dogs weighing 5-10 lbs, and 2 tablets per day for dogs weighing 11-25 lbs. For dogs weighing 26 lbs or more: The manufacturer recommends using the medium/large dog formulation and give one tablet per day for dogs weighing 26-50 lbs, 2 tablets per day for dogs weighing 51-100 lbs, and 4 tablets per day for dogs weighing 101-150 lbs. The tablets can be given at mealtime, or after mealtime. The tablets can be crushed or given to your pet whole. It is important to keep fresh water available at all times to your dog while they are taking Alenza.Treatment of ADH involves either surgical resection of the tumor or medical therapy with mitotane, trilostane, or ketoconazole. For many years, adrenalectomy has been considered the treatment of choice for ADH., However, there are no studies directly comparing surgical versus medical treatment for dogs with ADH. A number of factors should be considered before adrenalectomy, including the presence of metastatic lesions and concurrent diseases. In addition, adrenalectomy has reported frequencies of intraoperative and postoperative complications of 15–50% of affected dogs, respectively. Perioperative mortality rate of adrenalectomy is high (5–29%), , , and this could lead to unwillingness of the owner to accept the risk of this procedure. When surgery is not indicated or the owner declines surgery, medical management with the adrenocorticolytic drug mitotane has been recommended as an alternative treatment. The efficacy of mitotane has been described using the partial adrenocorticolysis protocol (PAP) in dogs with ADH. Alternatively, it has been proposed that nonselective adrenocorticolysis (NSAP) with mitotane might be useful in dogs with ADH, but there are no studies involving a large number of treated dogs. In the last decade, some studies have indicated that trilostane, a competitive inhibitor of 3ß‐hydroxysteroid dehydrogenase (3ß‐HSD), is a good option for the treatment of canine ADH., There is only 1 published study that compares the survival time of dogs with ADH treated either with mitotane or trilostane. The aims of this study were to compare the long‐term survival of dogs diagnosed with ADH treated with mitotane versus twice daily trilostane and to analyze epidemiologic, clinical and laboratory factors that might be associated with survival time. An additional aim was to identify any factors that might be used to determine the best medical treatment for this disease.